Halozyme Therapeutics Starts Trial of PEGPH20

Halozyme Therapeutics shares were up almost 1% pre-market Thursday after the company said it has initiated a multi-arm clinical trial evaluating PEGPH20 in combination with atezolizumab, an anti-PDL1 cancer immunotherapy from Genentech. The combination will be tested in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The study is sponsored and funded by Genentech.

The study is part of a clinical collaboration agreement announced by the companies last year to evaluate PEGPH20 and atezolizumab in up to eight tumor types, including pancreatic and gastric cancers. The trial is designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations compared with the standard chemotherapy regimens.

Leave a Comment